The company announced surprisingly striking revenue growth, in the financial time-frame ending December 31 2022

Considering the fourth quarter of 2022 earnings season CULL bottom-line turned positive at $0.12 per share, relative to the results of $-0.03 per share a year before financial reporting period, In the prior financial reporting period CULL realized $0.13 per share.

Cullman Bancorp Inc Competitors, Market Share

Cullman Bancorp Inc Revenue rise Rates

Conifer Holdings Inc disclosed Top-line was up moderately , amid the financial period closing Dec 31 2022

For the financial time-frame closing December 31 2022 CNFR had turn a round to profitability by exhibiting EPS of $0.15 per share compare to $-0.08 a year before and net profit per share turned positive from $-0.14 per share from the preceding reporting season.

Revenue increased slight by 3.692 % to $28.50 millions from $27.49 millions in the corresponding reporting season a year before and sequentially Revenues advanced by 8.232 % from $26.34 millions.

Conifer Holdings Inc Competitors, Market Share

Conifer Holdings Inc growth Rates, Profitability, PE

Business expenses were growing at the company in the most recent fiscal period

The stockholders haven't assumed some moderations at the revenue throughout the the earnings season of the October to December 31 2022 time at the RPHM. However, investors monitor the company's operating deficit that came in at $-14.562 millions, during the matching time.

Reneo Pharmaceuticals Inc Customers

Reneo Pharmaceuticals Inc Income Statement, Balance sheets, Cash Flow Statement

In the October to December 31 2022 company decreased a loss per share at $-0.98 per share, opposite of $-1.06 per share a year ago reporting period, In the previous reporting period Impel Pharmaceuticals Inc realized $-1.31 per share.

Impel Pharmaceuticals Inc Customers

Impel Pharmaceuticals Inc Income Statement, Balance sheets, Cash Flow Statement

Concentrating on the financial interval closing Dec 31 2022 CTMX lost money at $-0.42 per share, relative to the recent numbers of $-0.91 per share a year prior quarter, In the preceding quarter CTMX realized $-0.35 per share.

Cytomx Therapeutics Inc Customers

Cytomx Therapeutics Inc Suppliers

For the October to December 31 2022 span Acer Therapeutics Inc increased a deficit per share of $-0.54 per share compare to $-0.30 a year before and advanced deficit from $-0.31 per share from the previous quarter.

Revenues remained unaffected to $0.00 millions from $0.36 millions in the corresponding quarter a year before and sequentially Revenue Tumbled from $0.00 millions.

Acer Therapeutics Inc Customers

Acer Therapeutics Inc Suppliers

The company declared marginal reduction in their top-line, in the fourth quarter of 2022 earnings season

For the most recent fiscal period Pennsylvania Real Estate Investment Trust Diminishing Returns have swelled of $-7.81 per share compare to $-0.43 a year ago and Income per Share improved from $-14.52 per share from the previous financial reporting period.

Revenues decreased by -5.307 % to $80.65 millions from $85.17 millions in the same financial reporting period a year ago and sequentially Revenues advanced by 10.767 % from $72.81 millions.

Pennsylvania Real Estate Investment Trust Competitors, Market Share

Pennsylvania Real Estate Investment Trust elevation Rates, Profitability, PE

For the most recent fiscal period TERN decreased a loss per share of $-0.23 per share compare to $-0.56 a year before and Income per Share improved from $-0.44 per share from the previous quarter.

Revenues remained unscathed to $0.00 millions from $1.00 millions in the same quarter a year before and sequentially Revenues advanced from $0.00 millions.

Terns Pharmaceuticals Inc Suppliers

Terns Pharmaceuticals Inc Revenue advance Rates

For the fourth quarter of 2022 company lost money of $-0.14 per share compare to $-0.14 a year ago and from $0.00 per share from the prior financial reporting period.

Revenues remained unaltered by 0 % to $3.94 millions from $3.94 millions in the corresponding financial reporting period a year ago and sequentially Revenues advanced from $0.00 millions.

Gold Royalty Corp stock quotes, charts, profile

Gold Royalty Corp Income Statement, Balance sheets, Cash Flow Statement